GDC-0084, pilaralisib, buparlisib, XL765, and PX-866 are PI3K/mTOR inhibitors that can cross the BBB leading to their advancement to clinical trials for the treatment of GBM (Zhao et al., 2017; Colardo et al., 2021). Here, PIK3CA is linked to glioblastoma.